Short answer
MYRIAD GENETICS INC (MYGN) filed its Q2 2026 10-Q quarterly report on Jul 31, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $191M (down 10.5% year over year) with net income of −$43M.
Q2 2026 key financials · XBRL
- Revenue
- $191M
- −10.5% YoY · −4.8% QoQ
- Net income
- −$43M
- +86.9% YoY · −26.7% QoQ
- Operating margin
- -20.4%
- Gross margin
- 66.6%
- EPS (diluted)
- −$0.46
- +87.2% YoY · −27.8% QoQ
Source: XBRL data from the MYRIAD GENETICS INC (MYGN) Q2 2026 10-Q on SEC EDGAR. USD.
MYRIAD GENETICS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $190.7M, down $22.4M YoY, with $11.0M reduction from prior-period collection estimates
- Cost-of-revenue margin 33.4% vs 28.8% YoY, while sales and marketing expense reached 43.6% vs 33.7%
- Best segment Mental Health revenue $36.8M, down $1.0M; volume up 4% but revenue per test down 6%
- Worst segment Cancer Care Continuum revenue $114.1M, down $13.6M; revenue per test down 15%
- Credit facility interest rate 10.1% at June 30, 2026; management expects resources sufficient for at least 12 months
Risk Factors
- No new legal, regulatory, operational, competitive, market, liquidity, debt, currency, or concentration risks disclosed
- No equity repurchases or Rule 10b5-1 trading-plan activity during quarter ended June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MYRIAD GENETICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.